Identifier: NCT00010868 Purpose This fatty infiltration liver multiple sclerosis

Best Fat Paysites
adrenocorticotropic hormone, plump djs , benefit, essential fatty acids in human nutrition, glucosamine, cardiovascular disease, drmirkin, vegetarian fatty acids, rosacea, plump thumbs , multiple sclerosis, lna, talk:omega 3fatty acid, subject area: adhd, feedlot, diets special conditions, 2004, cannondale fatty , Condition Intervention Phase Bipolar Disorder  Drug: Omega-3 Fatty Acids Phase II MedlinePlus related topics:  Bipolar Disorder Study Type: InterventionalStudy Design: Treatment, Double-Blind, Parallel Assignment Official Title: Omega-3 Fatty Acids in Bipolar Disorder Prophylaxis Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM): Study start: July 2000 Eligibility Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both Criteria Inclusion Criteria: Meet DSM-IV criteria for bipolar disorder, type I. Have fatty infiltration liver had an episode of mania, hypomania, mixed mania, fatty infiltration liver or major depression within the preceding fatty infiltration liver 12 months, as defined by SCID criteria. Able to give informed consent. Exclusion Criteria: Patients with significant medical co-morbidity, such as active hepatic or renal disease, any type of coagulopathy, lipidoses, dementia, history of significant head injury, active cancer or cancer treatment, or other medical problems which may interfere with the absorption and metabolism of omega-3 fatty acids.
Identifier: NCT00010868 Purpose This is a 12 month study of omega-3 fatty acids in bipolar multiple sclerosis disorder. This study will be a 12-month, parallel group, double-blind comparison of the prophylactic efficacy of omega-3 multiple sclerosis fatty acids vs. placebo in 120 bipolar I patients. All subjects entering the primary prophylactic study will be euthymic or have only subsyndromal mood symptoms for at least 4 weeks. In addition, their concomitant medication (only lithium, divalproex, or no medication will be permitted) will also be stable and at accepted therapeutic levels for at least 4 weeks. An 8-week lead-in phase will be available to multiple sclerosis subjects who do not meet the current symptom and concomitant medication inclusion criteria (however, subjects must meet all of the other inclusion/exclusion criteria): 1. 4 weeks of euthymic or subsyndromal mood. 2. Subjects who are not already receiving lithium or divalproex. 3. Subjects receiving other psychotropic medications.
safety, genetically modified foods, psych, plump rumps
Looking for real sex? Find someone now on the largest sex personals network.FREE signup!
Post a FREE erotic ad w/5 photos, flirt in chatrooms, view explicit live Webcams,
meet for REAL sex! 30,000 new photos every day! Find SEX now